{'fraction_non_alphanumeric': 0.02208835341365462, 'fraction_numerical': 0.010040160642570281, 'mean_word_length': 5.397435897435898, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Medicines optimisation in England: where are we now?

In 2013, DTB described some of the challenges associated with the newly introduced and heavily promoted strategy of medicines optimisation with which the NHS attempted to “focus attention on outcomes rather than process in relation to improving quality, benefits and value for patients from their use of medicines”.1 Since then, what progress has been made in measuring and improving outcomes for patients as a result of ‘optimising’ medicines?